Skip to content

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

ATRA Atara Biotherapeutics, Inc
$4.47 3.60% +0.16
Notify me if price changes either direction
Interactive Brokers Logotype

Buy ATRA stocks now with Interactive Brokers – the most advanced investment platform

Contents
  • Performance
  • Key stats
  • Financials
  • US politician trades
Loading

Key Stats

Market cap. 32.1M
Enterprise value 35.3M
Trailing PE 1.5559441
Forward PE 6.238347
PEG Ratio -0.017467111927203
Enterprise to EBITDA 0.788
Enterprise to revenue 0.233
Price to book MRQ -1.6476442648905
Price to sales TTM 0.21118636

Financials

Fiscal Year Ends 2024-12-31
Most Recent Quarter (MRQ) 2025-09-30
Revenue (TTM) 151.9M
EBITDA 44.9M
Diluted EPS TTM 2.86
Total Cash (MRQ) 13.7M
Current ratio (MRQ) 1.021
Operating Cash Flow (TTM) -69714000

ATRA trades by the US politicians

Percentage
0% 0 sells
100% 0 buys
Amount
$0 0 sells
$0 0 buys
In the last 0 months

Recent ATRA News

Home

IMPORTANT NOTICE

Finbold is a news and information website. This Site may contain sponsored content, advertisements, and third-party materials, for which Finbold expressly disclaims any liability.

RISK WARNING: Cryptocurrencies are high-risk investments and you should not expect to be protected if something goes wrong. Don’t invest unless you’re prepared to lose all the money you invest. (Click here to learn more about cryptocurrency risks.)

By accessing this Site, you acknowledge that you understand these risks and that Finbold bears no responsibility for any losses, damages, or consequences resulting from your use of the Site or reliance on its content. Click here to learn more.